Zacks: Analysts Anticipate LivaNova PLC (LIVN) Will Announce Quarterly Sales of $277.83 Million

Analysts expect that LivaNova PLC (NASDAQ:LIVN) will report $277.83 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for LivaNova’s earnings, with the highest sales estimate coming in at $278.20 million and the lowest estimate coming in at $277.40 million. LivaNova posted sales of $321.40 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 13.6%. The firm is expected to announce its next earnings report on Wednesday, August 8th.

According to Zacks, analysts expect that LivaNova will report full year sales of $1.10 billion for the current fiscal year. For the next fiscal year, analysts expect that the business will post sales of $1.17 billion per share, with estimates ranging from $1.16 billion to $1.18 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for LivaNova.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 2nd. The company reported $0.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.03. LivaNova had a positive return on equity of 9.23% and a negative net margin of 1.99%. The business had revenue of $250.40 million for the quarter, compared to the consensus estimate of $245.18 million. During the same period in the previous year, the company posted $0.67 earnings per share. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year.

Several research analysts have recently weighed in on the company. ValuEngine upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research cut LivaNova from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. Needham & Company LLC restated a “buy” rating and issued a $104.00 price target (up previously from $97.00) on shares of LivaNova in a research note on Wednesday, February 28th. Stifel Nicolaus assumed coverage on LivaNova in a research note on Friday, June 8th. They issued a “buy” rating and a $115.00 price target for the company. Finally, BidaskClub upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 15th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. LivaNova currently has a consensus rating of “Buy” and an average price target of $85.88.

Shares of LivaNova traded down $0.51, hitting $101.14, during mid-day trading on Monday, Marketbeat reports. The company’s stock had a trading volume of 22,439 shares, compared to its average volume of 602,866. LivaNova has a 52-week low of $59.12 and a 52-week high of $105.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.85 and a quick ratio of 1.51. The stock has a market capitalization of $4.97 billion, a P/E ratio of 30.51, a P/E/G ratio of 3.02 and a beta of 0.76.

In related news, insider David S. Wise sold 1,500 shares of the company’s stock in a transaction on Friday, June 15th. The stock was sold at an average price of $104.46, for a total transaction of $156,690.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Damien Mcdonald sold 15,742 shares of the company’s stock in a transaction on Friday, June 8th. The shares were sold at an average price of $96.51, for a total value of $1,519,260.42. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,072 shares of company stock valued at $2,542,618. 0.41% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of LIVN. Aperio Group LLC increased its position in LivaNova by 21.4% in the fourth quarter. Aperio Group LLC now owns 6,810 shares of the company’s stock worth $544,000 after buying an additional 1,200 shares in the last quarter. Teacher Retirement System of Texas increased its position in LivaNova by 321.0% in the fourth quarter. Teacher Retirement System of Texas now owns 14,239 shares of the company’s stock worth $1,138,000 after buying an additional 10,857 shares in the last quarter. California Public Employees Retirement System increased its position in LivaNova by 6.6% in the fourth quarter. California Public Employees Retirement System now owns 159,169 shares of the company’s stock worth $12,721,000 after buying an additional 9,862 shares in the last quarter. New Mexico Educational Retirement Board purchased a new stake in LivaNova in the fourth quarter worth about $855,000. Finally, The Manufacturers Life Insurance Company increased its position in LivaNova by 8.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 105,580 shares of the company’s stock worth $8,438,000 after buying an additional 8,557 shares in the last quarter. Institutional investors and hedge funds own 84.62% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Get a free copy of the Zacks research report on LivaNova (LIVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply